Today, GenomeQuest and Cambridge Healthtech Associates reported on our healthcare industry calibration study on genomic interpretation This first-of-its kind calibration study on genomic interpretation surveyed over 55 industry leaders across twelve healthcare segments. Interview transcripts were reviewed by a panel of experts ...
Many of you know that GenomeQuest provides patent experts a market-leading research platform on biological sequences. While we're very much a standard in large pharma/AG globally and biotech in the US, we've recently begun a major initiative to engage and expand our biotech community in the EU. In support of this initiative, I had the ...
Last Wednesday, I woke up to a NYT article by Andrew Pollack on the "Deluge of Data" that seemingly haunts the genomics field. The very next morning, I awoke to a folder full of applications for the GenomeQuest NGS software grant for consolidated gene-panel tests. Talk about night and day! While it's reasonable to question ...
Last week, I attended the Personalized Medicine Conference (PMC) at HMS, moderated by Dr. Raju Kucherlapati. It was, yet again, outstanding in terms of quality of content, presenters, and networking. Immediately afterwards, GenomeQuest and NGS Leaders hosted over 30 moderators and Dx executives at a post-conference workshop to immediately exercise and apply ...
Last week, I attended the International Congress of Human Genetics conference in Montreal. Overall, it provided a wonderful and thorough update on the state of genetic research, practice, and plans – bravo to the show organizers and all presenters! Below are the top seven thoughts I heard in my sessions and around the ...
On the 40th anniversary of the National Cancer Act, the American Association of Cancer Research (AACR) this week issued its first "Cancer Progress Report". It's an outstanding, 84-page narrative that outlines the progress in our understanding/treatment of cancer and the criticality of genomics in transforming patient care going forward. You can download the full report here ...
In its third in a series of industry reports on the sequencing landscape, equity research specialist Macquarie Capital focused on the dynamics and opportunities in the clinical space. Included in the July 8, 2011 report: In as soon as three years, NGS testing could reach $3.6B in the U.S. (others have noted that MDx is the fasting ...
Last week's Forbes article noted that George Sledge, the president of the American Society of Clinical Oncology (ASCO), told his colleagues to prepare for a new era in which rapidly advancing genetic technology will change the way cancer is treated for the better. Sledge said, we are entering an era of “genomic chaos,” a phrase that ...
I have had the distinct pleasure of spending much time with Gerry Higgins during his consideration of an appointment at GenomeQuest. With his wealth of leadership experience at NIH, pharma, and directly in the hospital arena, I have found him among the most knowledgeable, prepared, and committed scientists to the immediate and broad application of ...
This news is a couple months old but significant nonetheless in several aspects (keep in mind: this is where the blood-thinning drug warfarin was discovered): Highlights: Researchers at the Medical College of Wisconsin are taking pioneering steps to make whole-genome sequencing a standard part of diagnostic testing for children with rare inherited disorders not easily ...